Stephen Denelsky Acquires 10,000 Shares of Harvard Bioscience (NASDAQ:HBIO) Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Director Stephen Denelsky purchased 10,000 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were bought at an average cost of $4.87 per share, with a total value of $48,700.00. Following the acquisition, the director directly owned 21,000 shares of the company’s stock, valued at $102,270. This trade represents a 90.91% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Harvard Bioscience Stock Up 14.8%

NASDAQ HBIO opened at $5.60 on Friday. Harvard Bioscience, Inc. has a 52 week low of $2.81 and a 52 week high of $9.50. The company has a quick ratio of 0.41, a current ratio of 2.20 and a debt-to-equity ratio of 2.61. The company has a market capitalization of $25.04 million, a P/E ratio of -0.44 and a beta of 1.51. The stock’s 50-day moving average price is $5.57 and its 200-day moving average price is $5.66.

Analyst Ratings Changes

Several brokerages have weighed in on HBIO. Benchmark lowered their price target on shares of Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating on the stock in a report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a report on Monday, December 29th. Zacks Research upgraded Harvard Bioscience to a “hold” rating in a research note on Thursday, December 11th. Finally, New Street Research set a $6.00 price target on Harvard Bioscience in a report on Friday, March 13th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its position in shares of Harvard Bioscience by 44.4% in the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after buying an additional 11,948 shares in the last quarter. Geode Capital Management LLC increased its stake in Harvard Bioscience by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 460,793 shares of the medical instruments supplier’s stock worth $308,000 after acquiring an additional 18,923 shares during the last quarter. Legato Capital Management LLC increased its stake in Harvard Bioscience by 210.4% in the 4th quarter. Legato Capital Management LLC now owns 43,467 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 29,462 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Harvard Bioscience by 291.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 37,057 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Harvard Bioscience during the 4th quarter worth approximately $26,000. Hedge funds and other institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.